May 16, 2017 — Here is a list of the late-breaking clinical trials presented at the Heart Rhythm Society (HRS) 2017 annual meeting May 10-13, in Chicago. The data presented is for the latest in electrophysiology (EP) clinical research, techniques and technologies. These trials were featured at Heart Rhythm 2017 and will be published in the July issue of the Heart Rhythm Journal.
Late-breaking Studies Presented at HRS 2017:
• The S-ICD Post-market Approval Study
• Intra-nasal Etripamil For Conversion Of Paroxysmal Supraventricular Tachycardia (PSVT). Node-1 Trial
• A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU (Apixaban Evaluation Of Interrupted Or Uninterrupted Anticoagulation For Ablation Of Atrial Fibrillation) Trial
• SPECT-guided Left Ventricular Lead Placement For Improved CRT Efficacy: A Randomized Controlled Trial
• Ranolazine in High-Risk ICD Patients (RAID) Trial
• The Nanostim Leadless Pacemaker: Battery Failures and Worldwide Chronic Device Retrieval
Other Key Presentations:
VIDEO: Editor's Choice of Most Innovative New Technology at HRS 2017
VIDEO: EP Lead Extraction Strategies, interview with Bruce Wilkoff, M.D.
VIDEO: Current State of Leadless Pacemaker Technology, interview with Vivek Reddy, M.D.
VIDEO: Overview of Subcutaneous ICD Technology
VIDEO: How to Start an Electrophysiology Program
Expert Consensus Released on Catheter, Surgical Ablation of Atrial Fibrillation
Watch the VIDEO interview with HRS President Michael Gold, M.D., on latest EP technology trends
Link to Heart Rhythm 2018 Late-breaking Studies
For more information: www.hrssessions.org